In vivo 2-deoxyglucose administration preserves glucose and glutamate transport and mitochondrial function in cortical synaptic terminals after exposure to amyloid beta-peptide and iron: evidence for a stress response

Exp Neurol. 2000 Nov;166(1):173-9. doi: 10.1006/exnr.2000.7497.

Abstract

Mild metabolic stress can increase resistance of neurons in the brain to subsequent more severe insults, as exemplified by the beneficial effects of heat shock and ischemic preconditioning. Studies of Alzheimer's disease and other age-related neurodegenerative disorders indicate that dysfunction and degeneration of synapses occur early in the cell death process, and that oxidative stress and mitochondrial dysfunction are central events in this pathological process. It was recently shown that administration of 2-deoxy-d-glucose (2DG), a nonmetabolizable glucose analog that induces metabolic stress, to rats and mice can increase resistance of neurons in the brain to excitotoxic, ischemic, and oxidative injury. We now report that administration of 2DG to adult rats (daily i.p. injections of 100 mg/kg body weight) increases resistance of synaptic terminals to dysfunction and degeneration induced by amyloid beta-peptide and ferrous iron, an oxidative insult. The magnitude of impairment of glucose and glutamate transport induced by amyloid beta-peptide and iron was significantly reduced in cortical synaptosomes from 2DG-treated rats compared to saline-treated control rats. Mitochondrial dysfunction, as indicated by increased levels of reactive oxygen species and decreased transmembrane potential, was significantly attenuated after exposure to amyloid beta-peptide and iron in synaptosomes from 2DG-treated rats. Levels of the stress proteins HSP-70 and GRP-78 were increased in synaptosomes from 2DG-treated rats, suggesting a mechanism whereby 2DG protects synaptic terminals. We conclude that 2DG bolsters cytoprotective mechanisms within synaptic terminals, suggesting novel preventative and therapeutic approaches for neurodegenerative disorders.

MeSH terms

  • ATP-Binding Cassette Transporters / drug effects
  • ATP-Binding Cassette Transporters / metabolism
  • Amino Acid Transport System X-AG
  • Amyloid beta-Peptides / adverse effects
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Brain Ischemia / drug therapy
  • Brain Ischemia / metabolism
  • Brain Ischemia / physiopathology
  • Carrier Proteins / drug effects
  • Carrier Proteins / metabolism
  • Cerebral Cortex / drug effects*
  • Cerebral Cortex / metabolism
  • Cerebral Cortex / pathology
  • Deoxyglucose / pharmacology*
  • Deoxyglucose / therapeutic use
  • Endoplasmic Reticulum Chaperone BiP
  • HSP70 Heat-Shock Proteins / drug effects
  • HSP70 Heat-Shock Proteins / metabolism
  • Heat-Shock Proteins*
  • Male
  • Mitochondria / drug effects*
  • Mitochondria / metabolism
  • Mitochondria / pathology
  • Molecular Chaperones / drug effects
  • Molecular Chaperones / metabolism
  • Monosaccharide Transport Proteins / drug effects
  • Monosaccharide Transport Proteins / metabolism
  • Nerve Degeneration / chemically induced
  • Nerve Degeneration / drug therapy*
  • Nerve Degeneration / physiopathology
  • Neurodegenerative Diseases / drug therapy*
  • Neurodegenerative Diseases / pathology
  • Neurodegenerative Diseases / physiopathology
  • Presynaptic Terminals / drug effects*
  • Presynaptic Terminals / metabolism
  • Presynaptic Terminals / pathology
  • Rats
  • Rats, Sprague-Dawley
  • Stress, Physiological / chemically induced*
  • Stress, Physiological / physiopathology
  • Synaptosomes / drug effects
  • Synaptosomes / metabolism

Substances

  • ATP-Binding Cassette Transporters
  • Amino Acid Transport System X-AG
  • Amyloid beta-Peptides
  • Carrier Proteins
  • Endoplasmic Reticulum Chaperone BiP
  • HSP70 Heat-Shock Proteins
  • Heat-Shock Proteins
  • Molecular Chaperones
  • Monosaccharide Transport Proteins
  • Deoxyglucose